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Abstract
Retrospective analysis of patient tumour samples is a
cornerstone of clinical research. CTC biomarker character‐
ization offers a non-invasive method to analyse patient
samples. However, current CTC technologies require
prospective blood collection, thereby reducing the ability
to utilize archived clinical cohorts with long-term outcome
data. We sought to investigate CTC recovery from frozen,
archived patient PBMC pellets. Matched samples from
both mCRPC patients and mock samples, which were
prepared by spiking healthy donor blood with cultured
prostate cancer cell line cells, were processed “fresh” via
Epic CTC Platform or from “frozen” PBMC pellets.
Samples were analysed for CTC enumeration and biomark‐
er characterization via immunofluorescent (IF) biomarkers,
fluorescence in-situ hybridization (FISH) and CTC mor‐
phology. In the frozen patient PMBC samples, the median
CTC recovery was 18%, compared to the freshly processed
blood. However, abundance and localization of cytokeratin
(CK) and androgen receptor (AR) protein, as measured by
IF, were largely concordant between the fresh and frozen
CTCs. Furthermore, a FISH analysis of PTEN loss showed
high concordance in fresh vs. frozen. The observed data
indicate that CTC biomarker characterization from frozen
archival samples is feasible and representative of prospec‐
tively collected samples.
Keywords Circulating Tumour Cells, Peripheral Blood
Mononuclear Cells, Metastatic Castrate Resistant Prostate
Cancer, Androgen Receptor, Biorepository
1. Introduction
The molecular characterization of circulating tumour cells
(CTCs) in the blood of patients with cancer has garnered
great interest for its potential to longitudinally monitor an
evolving disease, response to therapy and/or define
prognosis [1-5]. While numerous CTC technologies are in
development, a recognized unmet need is the ability to
retrospectively analyse CTC samples from previously
archived (frozen) clinical samples with associated long
clinical histories [6].
The Epic CTC Platform utilizes a non-enrichment-based
method  and  slide-based  immunofluorescence  (IF),
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coupled with digital pathology and genomic techniques,
to detect and molecularly characterize CTCs. As part of
the Epic Sciences standard operating procedures (SOPs),
blood tubes are shipped to Epic Sciences and processed
within 96 hours from blood draw. Following red blood
cell  (RBC)  lysis,  the  nucleated  fraction  is  plated  onto
microscope  slides  and  frozen  at  -80°C  for  storage  and
subsequent  analysis.  In  contrast,  many  enrichment-
based strategies are unable to store morphologically intact
CTCs for future analysis [7-9].  In order to augment the
Epic  SOP  for  sample  processing,  we  sought  to  deter‐
mine  if  the  Epic  Platform  might  be  compatible  with
previously  banked  (frozen)  patient  material  to  enable
retrospective analysis and expand the patient sample pool
amenable to Epic CTC characterization.
The collection of patient tissue, blood, saliva and urine is
common in clinical trials, often with peripheral blood
mononuclear cells (PBMCs) subjected to isolation and
cryopreservation [10]. Often, samples are banked until
retrospective analyses are initiated. To enable the retro‐
spective analysis of existing archived samples, we sought
to test whether CTCs could be detected and molecularly
characterized from pelleted, frozen PBMC fractions using
the Epic CTC Platform. We then compared the CTCs
recovered from these “frozen” samples with matched
material, which was prepared “fresh” per Epic SOP.
In this study, we report the enumeration and biomarker
characterization of spiked controls and patient samples,
which were processed fresh at Epic Sciences. These are
compared to matched samples from frozen/archived
PBMCs, which were prepared by Ficoll separation. We also
compare the morphological characteristics, protein expres‐
sion and genetic alterations of CTCs that were processed
using the Epic platform with CTCs from frozen PBMCs,
which had been stored up to 7.5 years prior to analysis.
2. Material and Methods
2.1 Preparation of Control Cell Line Cell (CLC) Slides
Healthy donor (HD) blood was collected in sodium heparin
Vacutainer® tubes (BD, Franklin Lakes, NJ) and whole
blood white blood cell (WBC) counts were recorded.
Known amounts of VCaP or PC3 (ATCC, Manassas, VA)
prostate cancer cell line cells (CLCs) were spiked into the
HD samples and nucleated cells were isolated by either the
Epic SOP or Ficoll density separation (Ficoll-Paque; GE
Healthcare, Buckinghamshire, UK), as per the manufactur‐
er’s protocol. For a description of the Epic SOP, please see
“Analytical Validation and Capabilities of the Epic CTC
Platform: Enrichment-Free Circulating Tumor Cell Detec‐
tion Characterization” [11]. WBC/PBMC counts were taken
after purification and were used to calculate the per cent
recovery. The recovered cell line-spiked PBMC pellets were
either: 1) used to create control CLC slides for IF staining
per Epic SOP via cell deposition on microscope slides and
storage in the Epic Biorepository, or 2) cryopreserved in
90/10 human AB serum/DMSO (Sigma-Aldrich, St. Louis,
MO) and stored in liquid nitrogen for at least 48 hours. The
cryopreserved PBMC pellets were then thawed and
deposited onto glass slides for staining and analysis or
storage in the Epic Biorepository.
2.2 Patient Blood Sample Processing
Blood samples were collected using Cell Free DNA BCT®
tubes (Streck, Omaha, NE) from metastatic castrate resist‐
ant prostate cancer (mCRPC) patients at the National
Cancer Institute and shipped to Epic Sciences for process‐
ing within 96 hours. All patients gave informed consent
and enrolled on a biospecimen collection protocol ap‐
proved by the NCI IRB (NCT00034216). Nucleated cells
were deposited onto glass slides and subsequently stored
at -80°C, as per Epic SOP. For matched patient blood
samples, two identical blood tubes were drawn. One tube
per patient was shipped immediately to Epic Sciences and
processed via SOP, while trained operators processed the
second tube at the clinical site via Ficoll separation. Ficoll
purified PBMCs were cryopreserved in 90/10 human AB
serum/DMSO and frozen in liquid nitrogen for up to 90
months prior to CTC analysis. Archived samples were
shipped frozen to Epic Sciences and processed with a
modified protocol for PBMC and CTC thaw and recovery,
followed by immediate cell deposition onto slides and
subsequent Epic Biorepository storage. For concordance
testing, matched samples were stained and processed
identically for morphology and biomarker assessment.
2.3 Cryopreserved CLC/CTC Thaw
For cryopreserved samples, the CLCs and patient samples,
which were stored in liquid nitrogen, were thawed in a
37°C water bath, followed by an immediate dilution with
RPMI 1640 medium supplemented with 10% foetal bovine
serum (Life Tech, Carlsbad, CA). The PBMCs were pelleted
and washed with PBS. This was followed by cell counting,
resuspension in plating medium and deposition onto glass
slides for -80°C storage and CTC analysis.
2.4 Immunofluorescent Staining and Analysis
Epic  Sciences’  CTC  identification  and  characterization
technology has been described in previous publications
[11,  12].  In  brief,  slides  created  from  CLC-spiked  HD
samples  or  mCRPC  patient  samples  were  subjected  to
automated  immunofluorescent  (IF)  staining  utilizing
commercially  available  monoclonal  primary  antibodies
against  pan-cytokeratin  (CK),  CD45  and  androgen
receptor  (AR).  Fluorescent-labelled  Alexa  Fluor  secon‐
dary antibodies (Life Tech, Carlsbad, CA) were used to
allow  for  fluorescent  detection  and  semi-quantitative
characterization of protein biomarkers. The stained slides
were analysed with automated fluorescent scanners and
morphology algorithms for the identification of tradition‐
al (CK+) CTCs, CTC clusters, small CTCs, apoptotic cells
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and CK-negative (CK-) CTCs. A more thorough descrip‐
tion  of  CTC  types  and  their  stage  of  validation  is
described  in  “Analytical  Validation  and Capabilities  of
the  Epic  CTC  Platform:  Enrichment-Free  Circulating
Tumor Cell  Detection Characterization” [11].  Trained
classifiers conduct a final classification of CTC subpopu‐
lations  and  record  subcellular  biomarker  localization,
where applicable.
2.5 Fluorescence in Situ Hybridization
Following CTC enumeration, IF and morphological
characterizations, select slides with sufficient CTCs were
further tested for genetic alterations by fluorescence in situ
hybridization (FISH). Coverslips were removed, immuno‐
fluorescence staining was attenuated and cells were fixed
and dehydrated with formaldehyde and ethanol, respec‐
tively. After dehydration, a probe solution targeting the
DNA sequences of interest (i.e., PTEN) was applied to each
slide, denatured for 10 minutes at 83°C and hybridized for
14-24 hours at 37°C. The slides were washed in a series of
saline sodium citrate (SSC)/detergent (Igepal) solutions,
counterstained with DAPI and mounted with an anti-fade
mounting medium. As the exact coordinates of every CTC
were recorded during the enumeration process, each CTC
can be relocated and analysed by FISH for specific genetic
alterations. Patient WBCs were used as internal controls,
representing the normal genetic status for each respective
sample.
2.6 Statistical Analyses
Statistical analyses were conducted using Graphpad Prism
software (La Jolla, CA). Kruskal-Wallis ANOVA was used
to compare the measures with >2 groups. A Mann-Whitney
U test was used to compare the differences between the
matched sample pairs from each individual patient. P<0.05
was considered to be significant.
3. Results
3.1 Androgen Receptor (AR)+ and AR- Cell Lines Demonstrate
Feasibility of CTC Recovery from Cryopreservation
To initially assess the capabilities of frozen CTC recovery
on the Epic Platform, CTC surrogate (VCaP (AR+) and PC3
(AR-)) CLCs were spiked into HD blood and subjected to
the same cell isolation, cryopreservation and sample
deposition protocols to be used for the processing of
archived patient samples (Figure 1A). Matched slides
containing CLCs that were deposited fresh or after freez‐
ing, were stained for CK, CD45 and AR. The concordance
of PBMC and CLC morphology, as well as protein expres‐
sion, were compared (Figure 2A). No statistically signifi‐
cant differences in recovery rates were observed between
CLCs that were processed with or without cryopreserva‐
tion (not shown). No significant changes in the mean AR
expression were seen in either VCaP or PC3 cells in frozen
samples, indicating the preservation of AR protein integri‐
ty. VCaP CK expression also remained unchanged, while
PC3 CK expression decreased by 35% in the frozen samples
(p<0.01). However, in the latter case, relative CK staining
intensity was still observed at 180-fold over WBC back‐
ground.
3.2 Concordance of CTC Recovery and Protein Expression from
Archived mCRPC Patient Samples
To determine concordance of patient CTC recovery and
characterization, two matched blood tubes were drawn
from 10 mCRPC patients. One tube was shipped to Epic
Sciences and processed within 96 hours using standard cell
deposition protocols (fresh), while the second tube was
subject to Ficoll PBMC isolation and archived in liquid
nitrogen (frozen; Figure 1B). Compared to the fresh
samples that were undergoing RBC lysis at Epic Sciences,
the Ficoll separation resulted in a lower net yield of
Figure 1. Schematic of sample preparation and experimental protocol for fresh and frozen sample processing. (A) To create control slides, cell line cells (CLCs)
were spiked into healthy donor blood and processed via Ficoll separation. CLC-containing PBMC pellets were split into identical fractions: one fraction was
cryopreserved in liquid nitrogen prior to cell deposition (blue arrow), and the other fraction was deposited fresh onto slides (grey arrow). (B) Matched mCRPC
patient samples were drawn: one sample was sent immediately to Epic Sciences for fresh sample deposition (grey arrow), and one sample was processed via
Ficoll and frozen at the clinical site. The frozen PBMC sample was cryopreserved for up to 7.5 years prior to shipment and subsequent processing at Epic
Sciences (blue arrow).
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nucleated cells due to the preferential enrichment for
PBMC over the whole WBC (median recovery: 67% and
20%, respectively; Figure 2B). Notably, the subsequent
freeze/thaw of the Ficoll isolated samples had no significant
effect on the net PBMC recovery (p>0.05), indicating that
the freeze/thaw process lost very little patient material.
The total CTCs and AR+ CTCs, as detected by IF staining,
were  normalized  to  7.5  mL  blood  volume  and  com‐
pared  between  the  freshly  processed  and  archived
samples (Figure 2C, D). CTCs were found in 8/10 of the
fresh samples and 8/10 of the frozen archived samples.
Typical CTC recovery in frozen samples was significant‐
ly lower as median CTC recovery in frozen samples was
18% that observed from freshly processed blood. Howev‐
er,  the  relative  order  of  CTC  burden  in  patients  re‐
mained  fairly  consistent,  with  the  exception  of  two
patients, NE1-8, -9. Furthermore, CTCs were found in the
fresh sample from patient NE1-15, which were undetect‐
ed in the matched frozen sample. Meanwhile, CTCs were
found in the frozen NE1-14 sample, which went undetect‐
ed in the corresponding fresh material. AR+ CTCs were
found in both preparations of NE1-13, -6 and -10, and the
median recovery of AR+ CTCs from the frozen samples
was  16%  of  that  observed  in  freshly  processed  blood.
Notably,  the  CTC  count  correlates  linearly  (though
sample  size  is  limited)  between  the  fresh  and  frozen
samples when normalized to blood volume or WBC count
(r2>0.90, n=10; Figure 3A, B). Additionally, the per cent of
AR+ CTC/CLC subpopulations also correlate between the
matched samples (r2=0.90, n=10; Figure 3C).
3.3 Cytokeratin and Androgen Receptor Expression is Retained
in Cryopreserved CTCs
Heterogeneous  CK  and  AR  protein  expression,  as
quantified by IF staining, was observed in all of the CTC
+ patients (Figure 3D, E). Moreover, traditional CK+ CTCs,
CTC clusters and CK- CTC subpopulations were found in
both the fresh and frozen material. With the exception of
NE1-6, in which the median CK expression was higher in
the  cryopreserved sample  (p<0.01),  no  other  significant
differences  in  CK  or  AR  protein  levels  were  observed
between the matched material.  Furthermore,  within the
AR+ CTCs, subpopulations with predominately nuclear-
localized AR as well as CTCs with diffuse cytoplasmic AR
were detected (representative images, Figure 4A, B). No
notable differences in the distribution of AR localization
were observed in the AR+ CTC subpopulations. (Figure
4C). Thus, the process of cryopreservation did not disrupt
the AR or CK protein localization in these samples.
Figure 2. Assessment of cell line and mCRPC patient CTC recovery. (A) The mean CLC CK and AR protein expression levels were compared between cells
that were processed fresh and after cryopreservation and thaw. The cryopreserved VCaP and PC3 samples showed a mean decrease in CK expression of 15%
(p>0.05) and 35% (p<0.001), respectively, compared to freshly processed cells. Mean VCaP and PC3 AR expression remained unchanged. (B) Compared to
whole blood WBC counts, the median WBC recovery in the patient samples that were processed fresh per Epic SOP was 67% (range: 32-79), while Ficoll
purification resulted in a median PBMC yield of 20% (range: 3.9-49). Ficoll-processed frozen sample recovery was not significantly changed post-thaw (p>0.05).
The total CTCs (C) and AR+ CTCs detected (D) from matched mCRPC patient blood draws, which were normalized to 7.5 mL blood, are plotted and tabulated
alongside control PC3 and VCaP CLC control slides. Patient CTCs were found in 8/10 of the fresh samples and 8/10 of the frozen samples. Compared to the
fresh samples, the median total and AR+ CTC recovery in the frozen samples were 18% and 16%, respectively. Notable differences: CTCs were found in the
fresh sample from patient NE1-15 but were undetected in the matched frozen sample, while CTCs were found in the frozen NE1-14 sample, which went
undetected in the fresh material. **p<0.01, ***p<0.001, n=10 patient samples.
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Figure 3. Comparison of CTC enumeration and biomarker expression. The CTCs that were recovered from the matched samples (or VCaP control) show a
linear correlation between the fresh and cryopreserved preparations when normalized to either 7.5 mL blood (A), 3M WBC (B), or (C) per cent AR+ CTCs
(r2≥0.90 for each comparison). CTCs with heterogeneous CK (D) and AR (E) expression levels were detected in the majority of patients from both the fresh (F)
and cryopreserved (C) samples. The dot plot depicts the presence of individual CTCs found in each patient sample. CK and AR positivity was defined for
any CTC with a relative protein expression of greater than 2.8- or 3-fold over background, respectively (dotted lines). With the exception of NE1-6 CK expression
(D; p<0.01), no other matched patient samples expressed significantly different levels of mean CK or AR protein between the fresh and frozen material (p>0.05;
Mann-Whitney U test).
Figure 4. Representative images of patient CTCs demonstrate the preservation of WBC and CTC morphology and retention of AR localization. Of the eight
patients with detectable CTCs, three patients harboured AR+ CTCs in both fresh and frozen samples. Representative images of AR- CTCs, nuclear AR+ CTCs
and diffuse cytoplasmic AR+ CTCs, which were recovered from both the fresh (A) and frozen (B) samples, are shown depicting preserved WBC and CTC
morphology and consistent biomarker localization. (C) Numerical assessment of AR localization in AR+ patients confirms the retention of subcellular protein
localization after CTC cryopreservation. The percentages of CTCs with nuclear or cytoplasmic localized AR are similar between the matched AR+ samples,
with no significant bias of localization between the fresh and frozen samples. (*>1300 CTCs present per slide; only 100 CTCs were assessed for AR localization.)
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3.4 Concordance of Genetic Assessment by FISH
To test the viability of downstream genetic analyses on
cryopreserved CTCs, PTEN FISH was conducted on patient
CTCs detected from freshly processed blood (Epic SOP)
and Ficoll-processed cryopreserved samples. In each
sample from patient NE1-13, at least 20 CTCs were assessed
for PTEN alterations. The assessment of homozygous
(PTEN = 0, CEP10 ≥ 1) and hemizygous (0 < PTEN < CEP10)
PTEN loss found near-equivalent populations of genetic
alterations between the fresh and frozen CTCs (Figure 5).
These findings demonstrate the preservation of DNA and
the feasibility of genetic analyses in cryopreserved CTCs.
3.5 CTC Recovery from Additional Banked mCRPC Patient
Samples
Cryopreserved mCRPC patient PBMC samples from a
previously completed clinical trial were shipped to Epic
Sciences for CTC recovery and characterization (5-92
months old). CTCs were detected in 16 of 20 (80%) samples,
with 11 patients also harbouring AR+ CTCs (Figure 6). Akin
to previously analysed samples, CTCs of varying morphol‐
ogy (i.e., traditional CK+, CTC clusters, apoptotic CTCs and
CK- CTCs) were found. Furthermore, heterogeneous CK
and AR protein levels and AR localization patterns were
observed in CTCs from these samples.
4. Discussion
In this study, we report enumeration and characterization
of morphology, biomarker expression, and genetic altera‐
tions of CTCs isolated from frozen PBMC fractions stored
up to 7.5 years prior to analysis. We found that patient
blood samples processed by Ficoll separation and cryopre‐
served in liquid nitrogen are amenable to CTC recovery
and characterization using the Epic Platform. The Ficoll
gradient method enriches for PBMCs, removing granulo‐
cytes and thus accounting for the decreased apparent yield
of nucleated cells after processing. Compared to the Epic
Sciences standard RBC lysis, this in part may account for
the decreased CTC recovery in samples processed by Ficoll.
However, the procedure of cryopreservation and sample
thaw alone does not substantially alter cell recovery,
indicating that the pre-analytic phase of nucleated cell
isolation may play a large role in influencing WBC/PBMC
(and presumably, CTC) recovery rates.
On average, approximately one quarter of the total CTC
counts were detected when the PBMCs were isolated via
Ficoll and frozen, as compared to the matched blood tubes,
Figure 5. Cryopreserved CTCs from PBMC pellets are viable for genetic analysis. After IF staining and protein characterization, patient CTCs recovered from
cryopreservation were assessed via PTEN FISH. CTC homozygous PTEN loss is defined as the complete absence of PTEN (10q23.31; green) signals with the
presence of ≥1 centromeric CEP10 (10p11.1-q11.1; red) signal(s) within the same cell. CTCs with present PTEN signals < CEP10 signals are indicative of
hemizygous PTEN loss. Preservation of WBC and CTC morphology was observed in frozen samples after fluorescent probe hybridization as well as a consistent
assessment of PTEN hemizygous loss in all CTCs assessed (95% & 90% PTEN loss in fresh and frozen material, respectively). Neighboring WBCs were used
as internal controls for normal genetic status and to establish proper assay specificity.
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which were sent immediately to Epic and banked fresh per
the Epic SOP. However, though absolute CTC recovery
diminishes in the archived samples, the relative abundance
of patient CTC burden, as well as the protein biomarker
(CK, AR) expression of those CTCs, remains largely
consistent with the matched fresh samples. In the case of
the archived samples, a decreased net CTC recovery can
potentially be overcome by testing a larger volume of
blood. Importantly, the archived CTCs demonstrate
preserved morphology, genetic alterations and biomarker
localization as compared to the fresh samples that were
received and processed within 96 hours. In our initial
feasibility study with matched mCRPC patient samples, we
were able to assess CTC CK and AR protein expression, AR
localization and PTEN status, all of which were found to be
largely concordant between the fresh and frozen material.
Taken together, all of the CTCs across all of the frozen
samples had a mean magnitude of CK and AR protein
expression 90% and 107% of matched freshly processed
material. Correlating these metrics between the matched
samples shows that the process described does not intro‐
duce a significant bias towards any given cell population.
Furthermore, no particular CTC subpopulation appears to
be favoured by cryopreservation. These findings suggest
that while precise longitudinal studies focused on CTC
enumeration may not be accurate given pre-analytic
variability (though relative abundance may be feasible),
genetic and protein characterization of archived CTCs is
possible on the Epic CTC Platform, enabling retrospective
biomarker validation studies in large cohorts of patients
with detailed clinical history.
In addition to these concordance studies, CTCs were
detected in an additional 16 of 20 advanced mCRPC
samples that were banked for up to 7.5 years prior to
analysis. Notably, no correlation was seen between sample
age and CTC recovery, and CTCs were found in both
baseline and follow-up draws. The data presented here
focus on the feasibility of studies based on archived
samples and do not themselves constitute a comprehensive
validation. Further work is underway to relate our findings
with clinical data and assess the ability to prognosticate
patient outcome based on data garnered from cryopre‐
served CTC analysis. Additionally, while we have ob‐
served close concordance of genetic PTEN alterations
between fresh and frozen CTCs from the same patient,
ongoing studies are working to relate CTC genetic altera‐
tions with incidence of mutations in both primary and
metastatic tumour tissue. A manuscript describing close
concordance of PTEN status between mCRPC CTCs
characterized on the Epic platform and solid tumour biopsy
Figure 6. Additional cryopreserved patient samples were processed via the Epic CTC Platform. Twenty additional cryopreserved mCRPC patient samples of
up to 7.5 years of age were processed. Similar to previously characterized matched samples, IF staining detected CK+ CTCs, CTC clusters, CK- CTCs and
apoptotic cells with heterogeneous CK (A) and AR (B) expression. The threshold for CK and AR positivity is 2.8- and 3-fold over background signals,
respectively (dotted lines). (C) Out of 20 samples, 16 (80%) had detectible CTCs (range: 2-40 CTCs/3M WBCs) and 11/16 (69%) CTC+ samples included AR+
CTCs (range: 1-10 CTCs/3M WBCs).
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tissue is currently under review for publication. Further‐
more, the feasibility of single cell picking on the Epic CTC
Platform coupled to next generation sequencing (NGS) has
been demonstrated as a proof of concept (manuscript in
preparation), and in-depth NGS characterization of
archived patient CTCs is underway.
The ability to retrospectively analyse samples from
completed prospective studies might yield additional CTC
biomarkers or insights into drug response or resistance
when more time-related clinical information, like PFS and
OS, are available. Retrospective genomic analyses have
been reported on “exceptional responder” patient samples
to define the likely mechanism of response to targeted
therapies [13, 14]. The ability to detect and characterize
material from archived patient blood samples offers the
potential for an additional window to augment archived
solid tissue biopsies for such analyses.
5. Compliance with Ethical Research Standards
All of the patients gave informed consent and enrolled on
a biospecimen collection protocol, approved by the NCI
IRB (NCT00034216).
6. Disclosures
DL, RPG, MH, SB, RK, JL, JW, NB, ML, DM and RD are
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